利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

63 条记录 (耗时 0.105 秒)

    Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
    6.
    发明授权
    Isothiazole dioxides as CXC- and CC-chemokine receptor ligands 失效
    异噻唑二氧化物作为CXC-和CC-趋化因子受体配体

    公开(公告)号：US07671212B2

    公开(公告)日：2010-03-02

    申请号：US11017505

    申请日：2004-12-20

    申请人： Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Junying Zheng ,  Purakkattle J. Biju ,  Younong Yu ,  Jianhua Chao ,  Gaifa Lai ,  Minglang Wu

    发明人： Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Junying Zheng ,  Purakkattle J. Biju ,  Younong Yu ,  Jianhua Chao ,  Gaifa Lai ,  Minglang Wu

    IPC分类号： A61K31/425 ,  C07D275/03

    CPC分类号： C07D275/03 ,  C07D417/12 ,  C07D417/14

    摘要： Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

    摘要翻译： 公开了下式的新化合物及其药学上可接受的盐和溶剂合物。 D和E是不同的组，其中一个是N，另一个是CR 50。 包含取代基A的基团的实例包括杂芳基，芳基，杂环烷基，环烷基，芳基，炔基，烯基，氨基烷基，烷基或氨基。 包含取代基B的基团的实例包括芳基和杂芳基。 还公开了治疗趋化因子介导的疾病如癌症，血管生成，血管生成性眼病，肺部疾病，多发性硬化，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，疼痛（例如急性疼痛，急性和慢性 炎症性疼痛和神经性疼痛）。

    Thiadiazoles as CXC- and CC- chemokine receptor ligands
    9.
    发明授权
    Thiadiazoles as CXC- and CC- chemokine receptor ligands 失效
    噻二唑作为CXC-和CC-趋化因子受体配体

    公开(公告)号：US07786149B2

    公开(公告)日：2010-08-31

    申请号：US11861870

    申请日：2007-09-26

    申请人： Purakkattle J. Biju ,  Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Younong Yu ,  Junying Zheng ,  Jianhua Chao ,  Cynthia J. Aki

    发明人： Purakkattle J. Biju ,  Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Younong Yu ,  Junying Zheng ,  Jianhua Chao ,  Cynthia J. Aki

    IPC分类号： C07D285/06 ,  A01N43/82

    CPC分类号： C07D285/10 ,  C07D285/06 ,  C07D417/12 ,  C07D417/14

    摘要： Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

    摘要翻译： 公开了下式的新化合物及其药学上可接受的盐和溶剂合物。 包含取代基A的基团的实例包括杂芳基，芳基，杂环烷基，环烷基，芳基，炔基，烯基，氨基烷基，烷基或氨基。 包含取代基B的基团的实例包括芳基和杂芳基。 还公开了治疗趋化因子介导的疾病，例如癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化，类风湿性关节炎，骨关节炎，中风和缺血再灌注损伤，疼痛（例如急性疼痛，急性和慢性 炎性疼痛和神经性疼痛），使用式IA化合物。

    Thiadiazoles AS CXC- and CC- chemokine receptor ligands
    10.
    发明授权
    Thiadiazoles AS CXC- and CC- chemokine receptor ligands 失效
    噻二唑AS CXC-和CC-趋化因子受体配体

    公开(公告)号：US07338968B2

    公开(公告)日：2008-03-04

    申请号：US11013753

    申请日：2004-12-16

    申请人： Purakkattle J. Biju ,  Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Younong Yu ,  Junying Zheng ,  Jianhua Chao ,  Cynthia J. Aki

    发明人： Purakkattle J. Biju ,  Arthur G. Taveras ,  J. Robert Merritt ,  John J. Baldwin ,  Younong Yu ,  Junying Zheng ,  Jianhua Chao ,  Cynthia J. Aki

    IPC分类号： C07D285/10 ,  A61K31/433

    CPC分类号： C07D285/10 ,  C07D285/06 ,  C07D417/12 ,  C07D417/14

    摘要： Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

    摘要翻译： 公开了下式的新化合物及其药学上可接受的盐和溶剂合物。 包含取代基A的基团的实例包括杂芳基，芳基，杂环烷基，环烷基，芳基，炔基，烯基，氨基烷基，烷基或氨基。 包含取代基B的基团的实例包括芳基和杂芳基。 还公开了治疗趋化因子介导的疾病，例如癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化，类风湿性关节炎，骨关节炎，中风和缺血再灌注损伤，疼痛（例如急性疼痛，急性和慢性 炎性疼痛和神经性疼痛），使用式IA化合物。